Create Medicines
Create Medicines
Developing in vivo immunotherapies for autoimmune diseases and cancer.
About
What does Create Medicines do?
Create Medicines is a biotechnology startup focused on developing in vivo immunotherapies. Their approach targets autoimmune diseases and cancer by leveraging the body's own immune system. The company has secured significant Series B funding to advance its research and development efforts.
What is Create Medicines's revenue?
StartupHub estimates Create Medicines's annual revenue at $15.8M (range $4.4M to $63.3M, 34% confidence), based on comparable companies in the sector.
What is Create Medicines's valuation?
StartupHub estimates Create Medicines's effective valuation at $512.4M (range $305.0M to $732.0M, 25% confidence), based on comparable companies in the sector.
How much funding has Create Medicines raised?
Create Medicines has raised a total of $122M in funding. The most recent round on record is Series B.
Where is Create Medicines headquartered?
Create Medicines is headquartered in Cambridge, Massachusetts, USA.
What industry does Create Medicines operate in?
Create Medicines operates in Biotechnology, HealthTech, Pharmaceuticals.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Develops and commercializes treatments for central nervous system disorders, including Rett syndrome.
A deep-tech company developing nanorobotic solutions for healthcare, initially targeting dental care applications.
MatrixCode is a research focus at the Freiburg Institute for Advanced Studies (FRIAS) investigating matrisome pathology.
A company focused on privacy, Zcash accumulation, and developing cancer therapeutics.
An entrant is a company tagged Biotechnology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.